Icon (NASDAQ:ICLR) CAO Sells $54,558.24 in Stock

Icon Plc (NASDAQ:ICLR) CAO Emer Lyons sold 264 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $206.66, for a total transaction of $54,558.24. Following the sale, the chief accounting officer owned 1,217 shares of the company’s stock, valued at $251,505.22. The trade was a 17.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emer Lyons also recently made the following trade(s):

• On Friday, October 23rd, Emer Lyons sold 272 shares of Icon stock. The stock was sold at an average price of $182.37, for a total transaction of $49,604.64.

Icon Price Performance

NASDAQ ICLR opened at $201.65 on Friday. The stock has a market capitalization of $15.44 billion, a P/E ratio of 34.71, a P/E/G ratio of 11.25 and a beta of 1.19. Icon Plc has a 1 year low of $66.57 and a 1 year high of $219.04. The business’s fifty day moving average is $174.57 and its two-hundred day moving average is $146.92. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.32 and a current ratio of 1.32.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Tuesday, October 27th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.01 billion. Icon had a return on equity of 7.73% and a net margin of 5.45%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.31 EPS. On average, research analysts forecast that Icon Plc will post 9.71 earnings per share for the current fiscal year.

Institutional Trading of Icon

Several hedge funds and other institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC boosted its stake in shares of Icon by 24.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 52,155 shares of the medical research company’s stock valued at $8,441,000 after buying an additional 10,389 shares during the period. Buckhead Capital Management LLC grew its holdings in shares of Icon by 0.9% during the 3rd quarter. Buckhead Capital Management LLC now owns 25,591 shares of the medical research company’s stock valued at $4,350,000 after acquiring an additional 218 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Icon by 13.5% in the third quarter. Commonwealth Equity Services LLC now owns 5,259 shares of the medical research company’s stock worth $894,000 after acquiring an additional 625 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its stake in shares of Icon by 0.4% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 20,762 shares of the medical research company’s stock worth $3,529,000 after acquiring an additional 79 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Icon during the third quarter worth $38,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ICLR. Citigroup increased their price target on Icon from $175.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, October 29th. TD Cowen boosted their price objective on Icon from $197.00 to $254.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Robert W. Baird upped their price objective on shares of Icon from $210.00 to $249.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. William Blair upgraded shares of Icon to a “strong-buy” rating in a report on Thursday, July 30th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $254.00 target price on shares of Icon in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $213.76.

About Icon

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.